Vault-13

PERCEPTIVE ADVISORS LLC

NEW YORK, NY · CIK 1224962 · 13F filing filed 2025-08-14

SEC-registered investment adviser since 2010 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
New York, NY (main office)United States United Statesabout 25
Greenwich, CTUnited States United States1
Miami Beach, FLUnited States United States1
Sheridan, WYUnited States United States1
Water Mill, NYUnited States United States

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$2.7bn reported value -5.5% vs Q1 2025
82positions
54.9%in top 10
19 new 12 added 33 reduced 23 sold out vs Q1 2025

Options: 1 call positions ($993.0k notional), 2 put positions ($31.3m notional) – listed below, not included above.

Holdings, Q2 2025

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 VERONA PHARMA PLC SPONSORED ADS VRNA VRNA 5,507,591 $520.9m19.55% 19.55% ReducedShares held: Q3 2024 6.3m, Q4 2024 6.4m, Q1 2025 6.6m, Q2 2025 5.5m -1.1m -1,055,749 -16.1%
2 ASCENDIS PHARMA A/S SPONSORED ADR SPONSORED ADR 963,886 $166.4m6.24% 6.24% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 963.9k
3 ARCELLX INC COMMON STOCK ACLX ACLX 2,478,000 $163.2m6.12% 6.12% ReducedShares held: Q3 2024 3.9m, Q4 2024 3.5m, Q1 2025 2.9m, Q2 2025 2.5m -448.5k -448,478 -15.3%
4 RHYTHM PHARMACEUTICALS INC COM RYTM RYTM 2,418,299 $152.8m5.73% 5.73% ReducedShares held: Q3 2024 3.6m, Q4 2024 3.7m, Q1 2025 2.5m, Q2 2025 2.4m -130.1k -130,146 -5.1%
5 NUVALENT INC COM COM 1,375,180 $104.9m3.94% 3.94% ReducedShares held: Q3 2024 3.0m, Q4 2024 2.6m, Q1 2025 1.6m, Q2 2025 1.4m -258.8k -258,788 -15.8%
6 ARTIVION INC COM AORT AORT 2,793,703 $86.9m3.26% 3.26% UnchangedShares held: Q3 2024 2.8m, Q4 2024 2.8m, Q1 2025 2.8m, Q2 2025 2.8m
7 MEIRAGTX HLDGS PLC COM MGTX MGTX 12,626,103 $82.2m3.09% 3.09% AddedShares held: Q3 2024 12.6m, Q4 2024 12.6m, Q1 2025 12.6m, Q2 2025 12.6m +45.0k +45,000 0.4%
8 INSMED INC COM PAR $.01 INSM INSM 650,252 $65.4m2.46% 2.46% AddedShares held: Q3 2024 180.0k, Q4 2024 144.0k, Q1 2025 509.3k, Q2 2025 650.3k +141.0k +140,952 27.7%
9 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 4,639,949 $60.8m2.28% 2.28% ReducedShares held: Q3 2024 2.3m, Q4 2024 2.7m, Q1 2025 6.5m, Q2 2025 4.6m -1.9m -1,907,379 -29.1%
10 PROTAGONIST THERAPEUTICS INC COM PTGX PTGX 1,074,448 $59.4m2.23% 2.23% ReducedShares held: Q3 2024 1.4m, Q4 2024 1.3m, Q1 2025 1.1m, Q2 2025 1.1m -16.8k -16,823 -1.5%
11 SOLID BIOSCIENCES INC COM NEW SLDB SLDB 11,906,646 $58.0m2.18% 2.18% UnchangedShares held: Q3 2024 6.9m, Q4 2024 6.9m, Q1 2025 11.9m, Q2 2025 11.9m
12 APOGEE THERAPEUTICS INC COM COM 1,182,148 $51.3m1.93% 1.93% AddedShares held: Q3 2024 2.0m, Q4 2024 1.0m, Q1 2025 1.1m, Q2 2025 1.2m +59.4k +59,381 5.3%
13 AMYLYX PHARMACEUTICALS INC COM AMLX AMLX 7,902,365 $50.7m1.90% 1.90% AddedShares held: Q3 2024 2.1m, Q4 2024 6.8m, Q1 2025 7.9m, Q2 2025 7.9m +28.0k +28,017 0.4%
14 IMMATICS N.V SHS IMTX IMTX 9,383,456 $50.5m1.89% 1.89% UnchangedShares held: Q3 2024 8.1m, Q4 2024 9.4m, Q1 2025 9.4m, Q2 2025 9.4m
15 AKERO THERAPEUTICS INC COM AKRO AKRO 915,887 $48.9m1.83% 1.83% AddedShares held: Q3 2024 1.7m, Q4 2024 1.2m, Q1 2025 793.0k, Q2 2025 915.9k +122.9k +122,927 15.5%
16 OMADA HEALTH INC COM OMDA OMDA 2,426,330 $44.4m1.67% 1.67% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 2.4m
17 AMICUS THERAPEUTICS INC COM FOLD FOLD 7,412,830 $42.5m1.59% 1.59% ReducedShares held: Q3 2024 28.1m, Q4 2024 24.2m, Q1 2025 21.5m, Q2 2025 7.4m -14.1m -14,051,697 -65.5%
18 ROIVANT SCIENCES LTD SHS ROIV ROIV 3,331,465 $37.5m1.41% 1.41% NewShares held: Q3 2024 847.7k, Q4 2024 0, Q1 2025 0, Q2 2025 3.3m
19 MERUS N V COM MRUS MRUS 708,176 $37.3m1.40% 1.40% AddedShares held: Q3 2024 300.0k, Q4 2024 300.0k, Q1 2025 690.5k, Q2 2025 708.2k +17.7k +17,691 2.6%
20 SOLENO THERAPEUTICS INC COM SLNO SLNO 430,439 $36.1m1.35% 1.35% ReducedShares held: Q3 2024 3.2m, Q4 2024 1.5m, Q1 2025 1.5m, Q2 2025 430.4k -1.1m -1,076,163 -71.4%
21 ASTRIA THERAPEUTICS INC COM CATB CATB 6,485,420 $34.8m1.30% 1.30% UnchangedShares held: Q3 2024 6.5m, Q4 2024 6.5m, Q1 2025 6.5m, Q2 2025 6.5m
22 IMMUNOVANT INC COM IMVT IMVT 2,137,890 $34.2m1.28% 1.28% ReducedShares held: Q3 2024 2.4m, Q4 2024 2.1m, Q1 2025 2.8m, Q2 2025 2.1m -706.2k -706,182 -24.8%
23 NEUROCRINE BIOSCIENCES INC COM NBIX NBIX 255,050 $32.1m1.20% 1.20% AddedShares held: Q3 2024 212.2k, Q4 2024 100.0k, Q1 2025 100.0k, Q2 2025 255.1k +155.0k +155,000 154.9%
24 PRAXIS PRECISION MEDICINES I COM NEW PRAX PRAX 752,921 $31.7m1.19% 1.19% ReducedShares held: Q3 2024 1.2m, Q4 2024 1.3m, Q1 2025 980.9k, Q2 2025 752.9k -228.0k -227,973 -23.2%
25 BOSTON SCIENTIFIC CORP COM BSX BSX 280,000 $30.1m1.13% 1.13% AddedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 130.0k, Q2 2025 280.0k +150.0k +150,000 115.4%
26 CARIS LIFE SCIENCES INC COM CAI CAI 1,098,163 $29.3m1.10% 1.10% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 1.1m
27 INTUITIVE SURGICAL INC COM NEW ISRG ISRG 45,119 $24.5m0.92% 0.92% AddedShares held: Q3 2024 58.1k, Q4 2024 63.1k, Q1 2025 40.6k, Q2 2025 45.1k +4.5k +4,500 11.1%
28 ADMA BIOLOGICS INC COM ADMA ADMA 1,303,468 $23.7m0.89% 0.89% ReducedShares held: Q3 2024 1.1m, Q4 2024 890.3k, Q1 2025 1.4m, Q2 2025 1.3m -69.8k -69,765 -5.1%
29 BETA BIONICS INC COM BBNX BBNX 1,593,608 $23.2m0.87% 0.87% UnchangedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 1.6m, Q2 2025 1.6m
30 SPYRE THERAPEUTICS INC COM NEW SYRE SYRE 1,529,445 $22.9m0.86% 0.86% ReducedShares held: Q3 2024 2.9m, Q4 2024 2.6m, Q1 2025 2.3m, Q2 2025 1.5m -783.8k -783,827 -33.9%
31 EVOLUS INC COM EOLS EOLS 2,474,843 $22.8m0.86% 0.86% ReducedShares held: Q3 2024 5.4m, Q4 2024 5.1m, Q1 2025 4.1m, Q2 2025 2.5m -1.7m -1,654,299 -40.1%
32 CELCUITY INC COM CELC CELC 1,633,208 $21.8m0.82% 0.82% ReducedShares held: Q3 2024 2.4m, Q4 2024 2.4m, Q1 2025 2.4m, Q2 2025 1.6m -729.1k -729,071 -30.9%
33 DYNE THERAPEUTICS INC COM DYN DYN 2,247,390 $21.4m0.80% 0.80% ReducedShares held: Q3 2024 718.1k, Q4 2024 543.3k, Q1 2025 2.3m, Q2 2025 2.2m -66.0k -66,013 -2.9%
34 SIONNA THERAPEUTICS INC COM SION SION 1,216,045 $21.1m0.79% 0.79% ReducedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 1.3m, Q2 2025 1.2m -35.1k -35,056 -2.8%
35 AXSOME THERAPEUTICS INC COM AXSM AXSM 198,534 $20.7m0.78% 0.78% ReducedShares held: Q3 2024 782.8k, Q4 2024 664.1k, Q1 2025 355.1k, Q2 2025 198.5k -156.6k -156,573 -44.1%
36 REPLIGEN CORP COM RGEN RGEN 166,000 $20.6m0.77% 0.77% AddedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 129.8k, Q2 2025 166.0k +36.2k +36,199 27.9%
37 INSULET CORP COM PODD PODD 60,387 $19.0m0.71% 0.71% ReducedShares held: Q3 2024 142.3k, Q4 2024 232.3k, Q1 2025 71.6k, Q2 2025 60.4k -11.2k -11,210 -15.7%
38 OUTSET MED INC COM NEW OM OM 833,333 $16.0m0.60% 0.60% UnchangedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 833.3k, Q2 2025 833.3k
39 ZYMEWORKS INC COM ZYME ZYME 1,275,274 $16.0m0.60% 0.60% ReducedShares held: Q3 2024 2.2m, Q4 2024 2.1m, Q1 2025 1.9m, Q2 2025 1.3m -589.4k -589,398 -31.6%
40 CYTOMX THERAPEUTICS INC COM CTMX CTMX 6,993,646 $15.9m0.60% 0.60% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 7.0m
41 ALDEYRA THERAPEUTICS INC COM ALDX ALDX 4,051,631 $15.5m0.58% 0.58% ReducedShares held: Q3 2024 9.3m, Q4 2024 9.3m, Q1 2025 9.3m, Q2 2025 4.1m -5.2m -5,224,220 -56.3%
42 CHARLES RIV LABS INTL INC COM CRL CRL 100,000 $15.2m0.57% 0.57% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 100.0k
43 CENTESSA PHARMACEUTICALS PLC SPONSORED ADS SPONSORED ADS 1,146,935 $15.1m0.57% 0.57% ReducedShares held: Q3 2024 6.3m, Q4 2024 6.3m, Q1 2025 3.0m, Q2 2025 1.1m -1.9m -1,893,460 -62.3%
44 INHIBRX BIOSCIENCES INC COM INBX INBX 977,892 $14.0m0.52% 0.52% ReducedShares held: Q3 2024 1.1m, Q4 2024 1.1m, Q1 2025 1.1m, Q2 2025 977.9k -86.1k -86,134 -8.1%
45 ADAGIO MED HLDGS INC COM ADGM ADGM 9,876,576 $12.8m0.48% 0.48% AddedShares held: Q3 2024 9.8m, Q4 2024 9.8m, Q1 2025 9.8m, Q2 2025 9.9m +64.2k +64,157 0.7%
46 NURIX THERAPEUTICS INC COM NRIX NRIX 1,096,985 $12.5m0.47% 0.47% AddedShares held: Q3 2024 0, Q4 2024 330.6k, Q1 2025 297.6k, Q2 2025 1.1m +799.4k +799,432 268.7%
47 TRAVERE THERAPEUTICS INC COM TVTX TVTX 834,252 $12.3m0.46% 0.46% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 834.3k
48 ORCHESTRA BIOMED HLDGS INC COM OBIO OBIO 4,592,556 $12.3m0.46% 0.46% UnchangedShares held: Q3 2024 4.6m, Q4 2024 4.6m, Q1 2025 4.6m, Q2 2025 4.6m
49 BRIGHT MINDS BIOSCIENCES INC COM NEW DRUG DRUG 420,690 $11.0m0.41% 0.41% ReducedShares held: Q3 2024 0, Q4 2024 403.6k, Q1 2025 444.6k, Q2 2025 420.7k -24.0k -23,959 -5.4%
50 INHIBIKASE THERAPEUTICS INC COM NEW IKT IKT 5,432,293 $10.6m0.40% 0.40% ReducedShares held: Q3 2024 0, Q4 2024 5.9m, Q1 2025 5.9m, Q2 2025 5.4m -492.7k -492,707 -8.3%
51 VIKING THERAPEUTICS INC COM VKTX VKTX 380,700 $10.1m0.38% 0.38% ReducedShares held: Q3 2024 1.7m, Q4 2024 995.9k, Q1 2025 509.0k, Q2 2025 380.7k -128.3k -128,305 -25.2%
52 ULTRAGENYX PHARMACEUTICAL IN COM RARE RARE 270,000 $9.8m0.37% 0.37% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 270.0k
53 KYMERA THERAPEUTICS INC COM KYMR KYMR 210,106 $9.2m0.34% 0.34% NewShares held: Q3 2024 46.2k, Q4 2024 0, Q1 2025 0, Q2 2025 210.1k
54 NAUTILUS BIOTECHNOLOGY INC COM NAUT NAUT 12,594,211 $9.1m0.34% 0.34% UnchangedShares held: Q3 2024 12.6m, Q4 2024 12.6m, Q1 2025 12.6m, Q2 2025 12.6m
55 PENUMBRA INC COM PEN PEN 32,797 $8.4m0.32% 0.32% NewShares held: Q3 2024 0, Q4 2024 73.3k, Q1 2025 0, Q2 2025 32.8k
56 CRESCENT BIOPHARMA INC. COM CBIO CBIO 453,686 $7.3m0.27% 0.27% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 453.7k
57 AQUESTIVE THERAPEUTICS INC COM AQST AQST 2,190,420 $7.3m0.27% 0.27% ReducedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 3.7m, Q2 2025 2.2m -1.5m -1,536,788 -41.2%
58 JANUX THERAPEUTICS INC COM JANX JANX 292,686 $6.8m0.25% 0.25% ReducedShares held: Q3 2024 0, Q4 2024 817.9k, Q1 2025 970.4k, Q2 2025 292.7k -677.7k -677,726 -69.8%
59 ANTERIS TECHNOLOGIES GLOBAL COM AVR AVR 1,705,130 $6.5m0.24% 0.24% ReducedShares held: Q3 2024 0, Q4 2024 2.1m, Q1 2025 2.1m, Q2 2025 1.7m -434.9k -434,870 -20.3%
60 XENON PHARMACEUTICALS INC COM XENE XENE 200,791 $6.3m0.24% 0.24% ReducedShares held: Q3 2024 524.9k, Q4 2024 325.3k, Q1 2025 325.3k, Q2 2025 200.8k -124.5k -124,533 -38.3%
61 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 447,507 $6.3m0.23% 0.23% ReducedShares held: Q3 2024 2.8m, Q4 2024 1.5m, Q1 2025 659.7k, Q2 2025 447.5k -212.2k -212,155 -32.2%
62 CORVUS PHARMACEUTICALS INC COM CRVS CRVS 1,438,595 $5.8m0.22% 0.22% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 1.4m
63 SEPTERNA INC COM SEPN SEPN 541,450 $5.7m0.21% 0.21% NewShares held: Q3 2024 0, Q4 2024 750.0k, Q1 2025 0, Q2 2025 541.5k
64 GLOBUS MED INC CL A GMED GMED 88,500 $5.2m0.20% 0.20% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 88.5k
65 ENVVENO MEDICAL CORPORATION COM COM 1,284,966 $5.1m0.19% 0.19% NewShares held: Q3 2024 694.3k, Q4 2024 0, Q1 2025 0, Q2 2025 1.3m
66 HELIX ACQUISITION CORP II CL A ORD SHS BBOT BBOT 398,000 $4.2m0.16% 0.16% UnchangedShares held: Q3 2024 500.0k, Q4 2024 500.0k, Q1 2025 398.0k, Q2 2025 398.0k
67 OPUS GENETICS INC COM IRD IRD 4,325,000 $4.1m0.15% 0.15% UnchangedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 4.3m, Q2 2025 4.3m
68 CONTINEUM THERAPEUTICS INC CL A CTNM CTNM 699,486 $2.8m0.10% 0.10% ReducedShares held: Q3 2024 1.5m, Q4 2024 1.4m, Q1 2025 1.4m, Q2 2025 699.5k -741.8k -741,763 -51.5%
69 LYRA THERAPEUTICS INC COM NEW LYRA LYRA 255,150 $2.3m0.09% 0.09% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 255.2k
70 SCPHARMACEUTICALS INC COM SCPH SCPH 500,000 $1.9m0.07% 0.07% UnchangedShares held: Q3 2024 0, Q4 2024 500.0k, Q1 2025 500.0k, Q2 2025 500.0k
71 ATHIRA PHARMA INC COM COM 5,402,964 $1.6m0.06% 0.06% UnchangedShares held: Q3 2024 5.4m, Q4 2024 5.4m, Q1 2025 5.4m, Q2 2025 5.4m
72 RAPT THERAPEUTICS INC COM NEW RAPT RAPT 183,890 $1.5m0.06% 0.06% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 183.9k
73 TRINITY BIOTECH PLC SPONS ADR NEW SPONS ADR NEW 1,790,000 $1.2m0.04% 0.04% NewShares held: Q3 2024 1.8m, Q4 2024 1.8m, Q1 2025 0, Q2 2025 1.8m
74 FORTE BIOSCIENCES INC COM NEW FBRX FBRX 68,192 $881.7k0.03% 0.03% NewShares held: Q3 2024 95.7k, Q4 2024 95.7k, Q1 2025 0, Q2 2025 68.2k
75 AVALO THERAPEUTICS INC COM NEW AVTX AVTX 139,667 $696.9k0.03% 0.03% ReducedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 520.0k, Q2 2025 139.7k -380.3k -380,333 -73.1%
76 BIODESIX INC COM COM 2,173,880 $613.0k0.02% 0.02% UnchangedShares held: Q3 2024 2.2m, Q4 2024 2.2m, Q1 2025 2.2m, Q2 2025 2.2m
77 LEXEO THERAPEUTICS INC COM LXEO LXEO 139,835 $562.1k0.02% 0.02% UnchangedShares held: Q3 2024 139.8k, Q4 2024 139.8k, Q1 2025 139.8k, Q2 2025 139.8k
78 APYX MEDICAL CORPORATION COM APYX APYX 150,000 $337.5k0.01% 0.01% UnchangedShares held: Q3 2024 0, Q4 2024 150.0k, Q1 2025 150.0k, Q2 2025 150.0k
79 KALA BIO INC COM NEW COM NEW 55,227 $262.9k0.01% 0.01% ReducedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 277.6k, Q2 2025 55.2k -222.4k -222,383 -80.1%
80 ENSYSCE BIOSCIENCES INC COM NEW ENSC ENSC 86,666 $193.3k0.01% 0.01% UnchangedShares held: Q3 2024 0, Q4 2024 86.7k, Q1 2025 86.7k, Q2 2025 86.7k
81 REVOLUTION MEDICINES INC *W EXP 12/17/202 RVMDW RVMDW 250,000 $65.7k0.00% 0.00% UnchangedShares held: Q3 2024 250.0k, Q4 2024 250.0k, Q1 2025 250.0k, Q2 2025 250.0k
82 SURROZEN INC *W EXP 08/01/203 *W EXP 08/01/203 166,666 $3.0k0.00% 0.00% UnchangedShares held: Q3 2024 166.7k, Q4 2024 166.7k, Q1 2025 166.7k, Q2 2025 166.7k

Sold out since Q1 2025

SecurityTickerShares held beforeValue then
INTRA-CELLULAR THERAPIES INC ITCI ITCI 786,358 $103.7m786.4k shares
IOVANCE BIOTHERAPEUTICS INC IOVA IOVA 12,711,788 $42.3m12.7m shares
ARGENX SE ARGX ARGX 59,510 $35.2m59.5k shares
VAXCYTE INC PCVX PCVX 706,567 $26.7m706.6k shares
MADRIGAL PHARMACEUTICALS INC MDGL MDGL 46,500 $15.4m46.5k shares
DEXCOM INC DXCM DXCM 178,000 $12.2m178.0k shares
ACRIVON THERAPEUTICS INC ACRV ACRV 5,360,858 $10.9m5.4m shares
CARGO THERAPEUTICS INC 2,431,085 $9.9m2.4m shares
EYEPOINT PHARMACEUTICALS INC EYPT EYPT 1,537,274 $8.3m1.5m shares
DISC MEDICINE INC IRON IRON 150,000 $7.4m150.0k shares
ADAPTIVE BIOTECHNOLOGIES COR ADPT ADPT 930,972 $6.9m931.0k shares
OCULAR THERAPEUTIX INC OCUL OCUL 915,775 $6.7m915.8k shares
DELCATH SYS INC DCTH DCTH 462,422 $5.9m462.4k shares
RAPT THERAPEUTICS INC 4,418,947 $5.4m4.4m shares
KESTRA MED TECHNOLOGIES LTD KMTS KMTS 200,000 $5.0m200.0k shares
ONKURE THERAPEUTICS INC OKUR OKUR 1,004,439 $4.3m1.0m shares
MEREO BIOPHARMA GROUP PLC MREO MREO 876,961 $2.0m877.0k shares
LYRA THERAPEUTICS INC LYRA LYRA 12,757,562 $1.6m12.8m shares
TRAWS PHARMA INC TRAW TRAW 421,781 $970.1k421.8k shares
ROCKET PHARMACEUTICALS INC RCKT RCKT 140,726 $938.6k140.7k shares
CULLINAN THERAPEUTICS INC CGEM CGEM 80,100 $606.4k80.1k shares
APPLIED THERAPEUTICS INC APLT APLT 860,000 $420.5k860.0k shares
NANOBIOTIX NBTX NBTX 105,053 $376.1k105.1k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
SPDR SER TR XBI · Put XBIPut 300,000 $24.9m300.0k shares New
CAPRICOR THERAPEUTICS INC CAPR · Put CAPRPut 650,000 $6.5m650.0k shares New
CAPRICOR THERAPEUTICS INC CAPR · Call CAPRCall 100,000 $993.0k100.0k shares New

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on. The largest 25 of 38.

CompanyTickerStakeChange ScheduleLast filed
ADAGIO MED HLDGS INC ADGM · 13G · filed 2026-05-15 ADGM 55.4%≈ $8.8m -2.1 pts 13G 2026-05-15
LEONABIO INC LONA · 13D · filed 2026-10-26 LONA 20.0%≈ $17.4m no change 13D 2026-10-26
LYRA THERAPEUTICS INC LYRA · 13D · filed 2025-08-14 LYRA 15.6% 13D 2025-08-14
MEIRAGTX HLDGS PLC MGTX · 13D · filed 2026-04-24 MGTX 12.6%≈ $158.6m -0.3 pts 13D 2026-04-24
SOLID BIOSCIENCES INC SLDB · 13D · filed 2026-08-14 SLDB 11.2%≈ $120.3m -1.7 pts 13D 2026-08-14
PERCEPTIVE CAP SOLUTIONS COR FRNM · 13G · filed 2026-07-23 FRNM 10.1% new 13G 2026-07-23
INHIBRX BIOSCIENCES INC INBX · 13G · filed 2026-08-14 INBX 10.0%≈ $141.1m no change 13G 2026-08-14
ALTO NEUROSCIENCE INC ANRO · 13G · filed 2026-08-14 ANRO 10.0%≈ $110.2m no change 13G 2026-08-14
OPUS GENETICS INC IRD · 13G · filed 2026-08-14 IRD 10.0%≈ $37.6m no change 13G 2026-08-14
ENGENE HOLDINGS INC 13G · filed 2026-08-14 10.0% no change 13G 2026-08-14
KIORA PHARMACEUTICALS INC KPRX · 13G · filed 2026-08-10 KPRX 10.0%≈ $1.2m new 13G 2026-08-10
ENVVENO MEDICAL CORPORATION 13G · filed 2026-02-17 10.0% 13G 2026-02-17
ORCHESTRA BIOMED HLDGS INC OBIO · 13G · filed 2025-11-14 OBIO 10.0%≈ $24.5m 13G 2025-11-14
TRINITY BIOTECH PLC 13D · filed 2026-05-04 9.9% no change 13D 2026-05-04
OUTSET MED INC OM · 13G · filed 2025-02-28 OM 9.5% new 13G 2025-02-28
NAUTILUS BIOTECHNOLOGY INC NAUT · 13D · filed 2026-08-14 NAUT 9.1%≈ $21.8m -1.0 pts 13D 2026-08-14
KARDIGAN INC KARD · 13D · filed 2026-10-01 KARD 8.8%≈ $196.9m -0.1 pts 13D 2026-10-01
QUINCE THERAPEUTICS INC IRLA · 13G · filed 2026-10-14 IRLA 8.4%≈ $1.7m new 13G 2026-10-14
RESEARCH ALLIANCE CORP III RACC · 13G · filed 2026-05-28 RACC 8.2%≈ $8.0m new 13G 2026-05-28
X4 PHARMACEUTICALS INC XFOR · 13G · filed 2026-08-14 XFOR 8.1%≈ $37.8m +0.8 pts 13G 2026-08-14
SUTRO BIOPHARMA INC STRO · 13G · filed 2026-08-14 STRO 7.9%≈ $43.3m +2.5 pts 13G 2026-08-14
PALISADE BIO INC PALI · 13G · filed 2026-05-15 PALI 7.9%≈ $29.5m -2.1 pts 13G 2026-05-15
IMMATICS N.V IMTX · 13D · filed 2026-08-27 IMTX 7.6%≈ $113.5m 13D 2026-08-27
AMYLYX PHARMACEUTICALS INC AMLX · 13G · filed 2026-05-15 AMLX 7.5%≈ $148.8m -0.7 pts 13G 2026-05-15
SAB BIOTHERAPEUTICS INC SABS · 13G · filed 2026-08-14 SABS 7.3%≈ $25.8m -1.1 pts 13G 2026-08-14

Trades reported as a company insider in Q2 2025

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2025-05-01 ACRIVON THERAPEUTICS INC 10% owner · See Footnote ACRV Sold 298,886 $400.5k298.9k shares -9%
2025-04-30 ACRIVON THERAPEUTICS INC 10% owner · See Footnote ACRV Sold 437,881 $617.4k437.9k shares -11%
2025-04-29 ACRIVON THERAPEUTICS INC 10% owner · See Footnote ACRV Sold 250,000 $352.5k250.0k shares -6%
2025-04-28 ACRIVON THERAPEUTICS INC 10% owner · See Footnote ACRV Sold 215,283 $335.8k215.3k shares -5%
2025-04-25 ACRIVON THERAPEUTICS INC 10% owner · See Footnote ACRV Sold 1,054,669 $2.1m1.1m shares -20%
2025-04-03 ALDEYRA THERAPEUTICS INC 10% owner · See Footnote ALDX Sold 3,400,000 $4.8m3.4m shares -37%